证券代码：603883 证券简称：老百姓 公告编号：2023-063 老百姓大药房连锁股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 老百姓大药房连锁股份有限公司（以下简称"公司"）已于 2023 年 10 月 31 日发布公司 2023 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2023 年第三季度经营成果、财务状况，公司计 划于 2023 年 12 月 13 日下午 15:00-16:30 举行 2023 年第三季度业绩 说明会，就投资者关心的问题进行交流。 会议召开时间：2023 年 12 月 13 日(星期三)下午 15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 12 月 06 日(星期三)至 12 月 12 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问 ...

证券代码：603883 证券简称：老百姓 公告编号：2023-061 老百姓大药房连锁股份有限公司 第四届董事会第三十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 一、董事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2023 年 11 月 14 日发出召开第四届董事会第三十二次会议的通知，会议于 2023 年 11 月 17 日在 公司会议室以现场加通讯表决的方式召开。本次董事会应出席董事 9 名，实际出 席董事 9 名，会议由董事长谢子龙先生主持。董事会秘书等相关人员列席会议。 本次会议经过了适当的通知程序，会议程序符合有关法律法规及《公司章程》的 规定，会议及通过的决议合法有效。 二、董事会会议审议情况 会议审议并通过了以下议案: （一）审议通过了《关于高级管理人员职务调整的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票，表决通过。 本议案已经公司第四届董事会提名、薪酬与考核委员会审议通过。 具体内容详见公司在上海证券交易所网站（http://www.sse. ...

Financial Performance - In the first three quarters of 2023, the company achieved revenue of CNY 16.042 billion, a year-on-year increase of 16.44%[4] - The retail pharmacy business accounted for 81.64% of total revenue, growing by 12.44% year-on-year, while the franchise and distribution business grew by 38.88% to represent 17.51% of total revenue[4] - The company reported a significant recovery in performance in October, following pressure in July and August due to healthcare reform impacts[5] - The company’s sales growth was supported by new store contributions of 2.98%, same-store sales growth of 4.6%, and acquisitions contributing approximately 4.34%[4] Store Expansion - The company opened 2,709 new stores in the first three quarters, bringing the total number of stores to 13,065, with a market share in ten provinces, including four with the highest market share[5] - The franchise business expanded rapidly, adding 1,230 new stores this year, with delivery sales reaching CNY 147 million, a 30% increase year-on-year[5] - The company added 1,230 franchise stores in the first three quarters of 2023, bringing the total to 4,120 franchise stores, which accounts for 31.5% of total stores[14] - The company plans to open 3,500 new stores annually over the next three years, maintaining a growth rate of approximately 25%[16] Digital and Operational Strategies - The company is focusing on a "development focus" strategy and "digital intelligence" strategy to enhance operational efficiency and market penetration[5] - The company achieved online sales of 1.49 billion, representing a year-on-year growth of 60% in the first three quarters of 2023[7] - As of the end of the reporting period, the company had 10,005 O2O delivery service stores and 632 24-hour stores[7] - The company has established a digital operation team specifically for outpatient coordination, with three internet hospitals and over ten external cooperative internet hospitals[12] Customer Engagement and Services - The total number of members reached over 83.12 million, with an increase of 3.89 million members during the reporting period[7] - The company aims to leverage policy benefits as more stores are included in the coordinated healthcare system, enhancing customer traffic and sales[5] - The company’s slow disease management services have recorded over 12 million patient files and 51 million self-testing instances[7] Competitive Positioning - The company aims to enhance its core competitiveness through improved brand recognition and supply chain management in response to franchise competition[14] - The company is committed to building a multi-format, full-industry chain health service ecosystem to drive growth[5] - The company’s gross margin is expected to improve through increased self-owned brand product offerings and enhanced digital management[17] - The company’s medical insurance revenue is on the rise, with medical insurance sales accounting for 54.9% of the sales in stores that can process outpatient insurance[11] Healthcare Coordination - The company has implemented outpatient coordination policies in 14 out of 20 provinces, with 2,893 stores eligible for coordination, representing 22.14% of total stores[6]

证券代码：603883 证券简称：老百姓 老百姓大药房连锁股份有限公司 2023 年三季度报告解读会纪要 一、会议情况 董事会秘书 冯诗倪 2.机构参会人员： 开源证券、浙商证券、恒泰证券、方正证券、中信建投、野村东方、申万宏源、 中银国际证券、长江资管、敦和资管、前海开源基金、南方基金、兴业基金、 中金基金、长城基金、鹏扬基金、博时基金、中欧基金、长信基金、中加基金、 博远基金、华夏基金、华宝基金、宝盈基金、嘉实基金、富达基金、嘉合基金、 汇安基金、中海基金、银河基金、浦银安盛基金、浦银安盛基金、雷沃基金、 湖南财信产业基金、汇百川基金、深圳中天汇富基金、长江资管、中银国际证 券资管、深圳前海岳瀚资管、海通证券资管、东方财富资管、国泰君安资管、 循远资管、国华兴益保险资管、天安人寿保险、北京金百镕投资、上海泊通投 资、上海雪石资管、上海玖鹏资管、上海和谐汇资管、深圳市尚诚资管、深圳 市千榕资管、上海景熙资管、上海牛乎资管、江西彼得明奇资管、深圳前海精 至资管、亘曦资产、镛泉资产、广州明曦投资管理、永安国富资管、敦和资管、 瑞信、福建豪山资管、华能贵诚信托、平安养老保险、工银国际、宁银理财、 华夏理财、杭州凯 ...

证券代码：603883 证券简称：老百姓 中金公司、海通证券、中信证券、中信建投、东吴证券、华创证券、国盛证券、 东北证券、招商证券、中邮证券、华鑫证券、华安证券、华西证券、国君证券、 广发证券、西南证券、安信证券、东吴证券、民生证券、平安证券、华泰证券、 开源证券、浙商证券、恒泰证券、方正证券、中信建投、野村东方、申万宏源、 中银国际证券、长江资管、敦和资管、前海开源基金、南方基金、兴业基金、 中金基金、长城基金、鹏扬基金、博时基金、中欧基金、长信基金、中加基金、 博远基金、华夏基金、华宝基金、宝盈基金、嘉实基金、富达基金、嘉合基金、 汇安基金、中海基金、银河基金、浦银安盛基金、浦银安盛基金、雷沃基金、 湖南财信产业基金、汇百川基金、深圳中天汇富基金、长江资管、中银国际证 券资管、深圳前海岳瀚资管、海通证券资管、东方财富资管、国泰君安资管、 循远资管、国华兴益保险资管、天安人寿保险、北京金百镕投资、上海泊通投 资、上海雪石资管、上海玖鹏资管、上海和谐汇资管、深圳市尚诚资管、深圳 市千榕资管、上海景熙资管、上海牛乎资管、江西彼得明奇资管、深圳前海精 至资管、亘曦资产、镛泉资产、广州明曦投资管理、永安国富资管、 ...

Financial Performance - The company's operating revenue for Q3 2023 was RMB 5,230,666,520, representing a year-on-year increase of 9.31%[4] - The net profit attributable to shareholders for Q3 2023 was RMB 203,315,056, an increase of 32.78% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 154,867,825, reflecting a 5.04% increase year-on-year[4] - Basic earnings per share for Q3 2023 were RMB 0.35, up 33.66% from the same period last year[6] - The net profit attributable to shareholders for the same period was 717 million RMB, an increase of 17.54% year-on-year[12] - The net profit for Q3 2023 was CNY 854,120,434, an increase of 19.7% compared to CNY 713,468,825 in Q3 2022[32] - The total profit for Q3 2023 reached CNY 1,069,863,843, up from CNY 858,047,096 in the same period last year, reflecting a growth of 24.7%[32] - The total comprehensive income attributable to the parent company for Q3 2023 was CNY 682,612,538, compared to CNY 550,402,023 in Q3 2022, marking a growth of 23.9%[33] Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2023 was RMB 392,158,827, a decrease of 55.85% compared to the previous year[6] - The company's cash and cash equivalents decreased from approximately 2.41 billion in December 2022 to approximately 1.95 billion by September 30, 2023[27] - The net cash flow from operating activities for the first three quarters of 2023 was CNY 18,663,231,873, an increase of 19.2% from CNY 15,656,823,436 in the same period of 2022[34] - The net cash flow from investing activities for Q3 2023 was CNY (343,615,820), a significant decrease compared to CNY (1,563,299,012) in Q3 2022[35] - The total cash and cash equivalents at the end of Q3 2023 were CNY 1,028,321,991, down from CNY 1,451,238,745 at the end of Q3 2022[35] Assets and Liabilities - Total assets at the end of Q3 2023 were RMB 21,325,004,356, a slight decrease of 0.34% from the end of the previous year[6] - The total liabilities decreased to ¥14,072,910,973 in Q3 2023 from ¥14,299,609,510 in the previous quarter, showing a reduction of about 1.6%[29] - Inventory levels increased to ¥4,099,036,813 in Q3 2023 from ¥3,948,892,852 in the previous quarter, indicating a rise of approximately 3.8%[29] Store Expansion and Operations - The company opened 2,709 new stores in the first nine months of 2023, including 1,479 direct stores and 1,230 franchise stores[16] - As of September 30, 2023, the company had a total of 13,065 stores, with 8,945 being direct stores and 4,120 franchise stores[16] - The company expanded its store network to 13,065 locations, with 8,945 direct stores and 4,120 franchise stores, as of September 30, 2023[22] - The company’s direct store daily sales efficiency was 53 RMB/square meter, with a decline in efficiency for smaller stores compared to the previous year[18] Shareholder Information - The top shareholder, Laobaixing Pharmaceutical Group Co., Ltd., holds 26.10% of the shares, with a total of 152,741,673 shares[10] - The equity attributable to shareholders at the end of Q3 2023 was RMB 6,667,549,624, an increase of 2.11% compared to the end of the previous year[6] Strategic Initiatives - The company has implemented a three-dimensional strategy to enhance operational execution in response to outpatient management policies, covering 14 provinces[23] - The company aims to build a technology-driven health service platform, enhancing supply chain efficiency and digital governance[23] Sales and Marketing - The company achieved a 30% year-on-year growth in alliance business sales, reaching 1.47 million yuan in the first three quarters of 2023[23] - The company reported a 60% year-on-year increase in online channel sales, totaling 1.49 billion yuan in the first three quarters of 2023[23] - The company’s membership sales accounted for 86.6% of total sales in September, with a 67.5% repurchase rate within 90 days[23] Research and Development - Research and development expenses for Q3 2023 were reported at ¥686,634, reflecting ongoing investment in innovation[30] Acquisitions - The company completed 8 acquisition projects in the first nine months of 2023, totaling 726.26 million RMB, acquiring 351 pharmacies[20] - The company acquired assets and businesses from 17 stores for a total price of 7.3 million yuan in March 2023[21] - The company purchased 80% equity of a restructured company with 129 stores for 124 million yuan in March 2023[21] - The company acquired 100% equity of another restructured company with 102 stores for 131 million yuan in March 2023[21] - The company purchased 23% equity of a health pharmacy group for 247.57 million yuan in April 2023[21] Employee Training - The company’s training success rates for frontline staff were 99.2% for new employees and 99.7% for store manager trainees in Q3 2023[24]

证券代码：603883 证券简称：老百姓 公告编号：2023-055 老百姓大药房连锁股份有限公司 第四届董事会第三十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 重要内容提示： 一、董事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2023 年 10 月 20 日发出召开第四届董事会第三十一次会议的通知，会议于 2023 年 10 月 30 日在 公司会议室以现场加通讯表决的方式召开。本次董事会应出席董事 9 名，实际出 席董事 9 名，会议由董事长谢子龙先生主持。董事会秘书等相关人员列席会议。 本次会议经过了适当的通知程序，会议程序符合有关法律法规及《公司章程》的 规定，会议及通过的决议合法有效。 表决结果：同意 9 票，反对 0 票，弃权 0 票，表决通过。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）公告的《老 百姓 2023 年第三季度报告》（公告编号：2023-057）。 （二）审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》 ...

证券代码：603883 证券简称：老百姓 公告编号：2023-059 老百姓大药房连锁股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 重要内容提示： ● 老百姓大药房连锁股份有限公司（以下简称"公司"或"老百姓"）本次使用 闲置募集资金暂时补充流动资金的金额为人民币 40,000 万元。 ● 公司募集资金暂时补充流动资金的使用期限：自公司董事会审议通过之日 起不超过 6 个月。 ● 公司于 2023 年 10 月 30 日召开第四届董事会第三十一次会议和第四届监 事会第二十六次会议审议通过了《关于使用部分闲置募集资金暂时补充流动资金 的议案》，同意公司使用不超过 40,000 万元暂时闲置的募集资金暂时补充流动 资金。现将相关事宜公告如下： 一、募集资金基本情况 二、发行申请文件承诺募集资金使用情况 截至 2023 年 10 月 26 日，公司非公开发行股票募集资金余额为 64,539.99 万 元（包含利息、手续费以及发行费用的影响），具体使用情况如下表所 ...

证券代码：603883 证券简称：老百姓 公告编号：2023-058 老百姓大药房连锁股份有限公司 关于 2023 年三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 （3）主要业务分区域情况 | 分地区 | 营业收入（元） | 营业收入比上年增减（%） | | --- | --- | --- | | 华中区域 | 6,981,637,344 | 16.77 | | 华南区域 | 824,381,544 | 5.55 | | 华北区域 | 2,032,336,971 | 10.89 | | 华东区域 | 4,024,050,880 | 18.42 | | 西北区域 | 2,179,120,102 | 22.06 | | 合计 | 16,041,526,841 | 16.44 | 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司2023年第三季度报告披露工作的重要提醒》相关要求，现将老百姓大药 房连锁股份有限公司（以下简称"公司"）2023年三季度主要经营数据披露如下： ...

老百姓大药房连锁股份有限公司独立董事 关于第四届董事会第三十一次会议相关事项的 二、关于收购扬州市百信缘医药连锁有限公司 35%股权的议案 公司收购收购扬州市百信缘医药连锁有限公司 35%股权符合公司整体战略 规划，有利于公司进一步加强对百信缘的控制，整合企业资源，提高对百信缘的 管理效率，充分发挥公司与百信缘在江苏地区的规模效应和协同优势，进一步增 强公司核心竞争力和综合盈利能力。本次交易不存在损害公司及股东利益的情形。 公司董事会审议该议案时，程序规范，符合法律、法规和公司章程的相关规 独立意见 根据《公司法》《证券法》《上海证券交易所股票上市规则》《上市公司独立 董事规则》等法律、法规及《公司章程》的有关规定，我们作为老百姓大药房连 锁股份有限公司（以下简称"公司"）的独立董事，本着认真、负责的态度，基 于独立、客观、审慎的原则，对提交公司第四届董事会第三十一次会议的审议事 项进行了认真审阅，现就相关议案发表独立意见如下： 一、关于使用部分闲置募集资金暂时补充流动资金的议案 鉴于公司部分募集资金处于闲置状态，在不影响募集资金投资计划的正常进 行、不变相改变募集资金用途的前提下，使用其中部分闲置的募集资金 ...